{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:08:22Z","timestamp":1791403702324,"version":"4.3.3"},"reference-count":22,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.clml.2022.04.018","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T02:46:07Z","timestamp":1650595567000},"page":"702-707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Long-Term Complete Clinical and Hematological Response With Bortezomib: The Report of a Case With TEM(P)I Syndrome and a Review of the Literature"],"prefix":"10.1016","volume":"22","author":[{"given":"Levent","family":"Undar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5897-6514","authenticated-orcid":false,"given":"Unal","family":"Atas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utku","family":"Iltar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozan","family":"Salim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhan Kemal","family":"Yucel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkan","family":"Alpsoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.04.018_bib0001","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1056\/NEJMc1106670","article-title":"The TEMPI syndrome \u2014a novel multisystem disease","volume":"365","author":"Sykes","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.04.018_bib0002","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"key":"10.1016\/j.clml.2022.04.018_bib0003","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1182\/blood.2019004216","article-title":"The TEMPI syndrome","volume":"135","author":"Sykes","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.018_bib0004","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1056\/NEJMc1205806","article-title":"Complete and partial responses of the TEMPI syndrome to bortezomib","volume":"367","author":"Schroyens","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.04.018_bib0005","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/ckj\/sfs139","article-title":"A new case of TEMPI syndrome","volume":"5","author":"Mohammadi","year":"2012","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.clml.2022.04.018_bib0006","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1056\/NEJMc1202649","article-title":"Bortezomib to Treat the TEMPI ayndrome","volume":"366","author":"Kwok","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.04.018_bib0007","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/ndt\/gfr433","article-title":"Perirenal fluid collections and monoclonal gammopathy","volume":"27","author":"Viglietti","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clml.2022.04.018_bib0008","doi-asserted-by":"crossref","first-page":"927A","DOI":"10.1378\/chest.1701121","article-title":"Toomuch blood: a case of the newly described TEMPI syndrome","volume":"144","author":"Ryden","year":"2013","journal-title":"CHEST"},{"key":"10.1016\/j.clml.2022.04.018_bib0009","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1016\/j.clml.2014.07.004","article-title":"Subcutaneous bortezomib for treatment of TEMPI syndrome","volume":"14","author":"Jasim","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.clml.2022.04.018_bib0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/2052-1839-14-11","article-title":"Case report: a 37-year-old male with telangiectasias, polycythemia vera, perinephric fluid collections, and intrapulmonary shunting","volume":"14","author":"Khan","year":"2014","journal-title":"BMC Hematol"},{"key":"10.1016\/j.clml.2022.04.018_bib0011","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1038\/leu.2015.298","article-title":"Long-term complete clinical and hematological responses of the TEMPI syndrome after autologous stem cell transplantation","volume":"29","author":"Kenderian","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.04.018_bib0012","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1111\/trf.13125","article-title":"Difficulties in hematopoietic progenitor cell collection from a patient with TEMPI syndrome and severe iatrogenic iron deficiency","volume":"55","author":"Belizaire","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.clml.2022.04.018_bib0013","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.jbspin.2015.06.011","article-title":"Coexistence of rheumatoid arthritis and TEMPI syndrome: new insight in microangiogenic-related diseases","volume":"83","author":"Pascart","year":"2016","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.clml.2022.04.018_bib0014","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1007\/s00277-019-03761-4","article-title":"Relapsed multiple myeloma as TEMPI syndrome with good response to salvage lenalidomide and dexamethasone","volume":"98","author":"Liang","year":"2019","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.clml.2022.04.018_bib0015","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.2169\/internalmedicine.3547-19","article-title":"The first case of TEMPI syndrome in Japan","volume":"59","author":"Shizuku","year":"2020","journal-title":"Intern Med"},{"key":"10.1016\/j.clml.2022.04.018_bib0016","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2020.2668","article-title":"TEMPI syndrome with progressive telangiectasias associated with pulmonary deterioration","author":"Lor","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clml.2022.04.018_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106441","article-title":"A fatal case of TEMPI syndrome, refractory to proteasome inhibitors and autologous stem cell transplantation","volume":"97","author":"Diral","year":"2020","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2022.04.018_bib0018","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jdcr.2021.02.022","article-title":"Diffuse telangiectasia: a clue to the TEMPI syndrome","volume":"10","author":"Ruan","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.clml.2022.04.018_bib0019","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1182\/bloodadvances.2020003783","article-title":"Whole-genome sequencing suggests a role of MIF in the pathophysiology of TEMPI syndrome","volume":"5","author":"Sun","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.04.018_bib0020","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/jdv.17539","article-title":"Cutaneous ulceration as primary presentation of TEMPI syndrome","volume":"35","author":"Strobl","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clml.2022.04.018_bib0021","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.clml.2018.07.284","article-title":"TEMPI syndrome: erythrocytosis in plasma cell dyscrasia","volume":"18","author":"Zhang","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.04.018_bib0022","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/modpathol.2014.117","article-title":"Bone marrow findings of the newly described TEMPI syndrome: when erythrocytosis and plasma cell dyscrasia coexist","volume":"28","author":"Rosado","year":"2015","journal-title":"Mod Pathol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502200132X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502200132X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:40:44Z","timestamp":1761871244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502200132X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S215226502200132X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.04.018","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Complete Clinical and Hematological Response With Bortezomib: The Report of a Case With TEM(P)I Syndrome and a Review of the Literature","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}